The Effects of Diosgenin on Hypolipidemia and Its Underlying Mechanism: A Review

Fengcui Sun1, Xiufen Yang1, Chaoqun Ma1, Shizhao Zhang1, Lu Yu2, Haifei Lu3, Guoliang Yin1, Pengpeng Liang1, Yanan Feng1, Fengxia Zhang4

1Shandong University of Traditional Chinese Medicine, Jinan, 250000, People’s Republic of China; 2Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, People’s Republic of China; 3Hubei University of Traditional Chinese Medicine, Wuhan, 430065, People’s Republic of China; 4Department of Neurology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250011, People’s Republic of China

Abstract: Hyperlipidemia is a disorder of lipid metabolism, which is a major cause of coronary heart disease. Although there has been considerable progress in hyperlipidemia treatment, morbidity and risk associated with the condition continue to rise. The first-line treatment for hyperlipidemia, statins, has multiple side effects; therefore, development of safe and effective drugs from natural products to prevent and treat hyperlipidemia is necessary. Diosgenin is primarily derived from fenugreek (Trigonella foenum graecum) seeds, and is also abundant in medicinal herbs such as Dioscorea rhizome, Dioscorea septemloba, and Rhizoma polygonati, is a well-known steroidal sapogenin and the active ingredient in many drugs to treat cardiovascular conditions. There is abundant evidence that diosgenin has potential for application in correcting lipid metabolism disorders. In this review, we evaluated the latest evidence related to diosgenin and hyperlipidemia from clinical and animal studies. Additionally, we elaborate the pharmacological mechanism underlying the activity of diosgenin in treating hyperlipidemia in detail, including its role in inhibition of intestinal absorption of lipids, regulation of cholesterol transport, promotion of cholesterol conversion into bile acid and its excretion, inhibition of endogenous lipid biosynthesis, antioxidation and lipoprotein lipase activity, and regulation of transcription factors related to lipid metabolism. This review provides a deep exploration of the pharmacological mechanisms involved in diosgenin-hyperlipidemia interactions and suggests potential routes for the development of novel drug therapies for hyperlipidemia.

Keywords: diosgenin, hyperlipidemia, serum cholesterol, lipoprotein cholesterol, mechanism

Introduction

Hyperlipidemia is a pathological disorder of lipid metabolism that has various causes. The clinical manifestations of hyperlipidemia include increased serum cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C), and decreased serum high-density lipoprotein cholesterol (HDL-C). Imbalance of LDL-C and HDL-C can increase the risk of cardiovascular (CV) events, including myocardial infarction and stroke.1 Data released by the American Heart Association in 2018 showed that CV disease (CVD) is the most lethal disease worldwide.2 According to the 2010 global burden of disease study, 15.6 million people died of CVD, accounting for 29.6% of all deaths.3 Hyperlipidemia has a long disease course, and many underlying causes, reflecting its complex etiology.4 Dyslipidemia is a significant risk factor for coronary artery disease and stroke; hence, prevention and appropriate management of dyslipidemia can markedly lower the related morbidity and mortality.5 Holven et al described the importance of early...
identification and treatment of patients with familial hypercholesterolemia for reducing cholesterol burden and risk of CHD. Lipid-lowering therapy is a cornerstone of CV risk modification strategies, which can reduce LDL-C by 30–50% and proportionally reduce CV events. Although statins are generally well tolerated, they are not always sufficient to achieve LDL-C goals for many patients, and cause numerous specific negative effects on muscle, liver, and kidney, as well as increasing the risk of new-onset diabetes mellitus and hemorrhagic stroke. Therefore, there is an urgent need to develop new powerful drugs to treat hyperlipidemia and reduce the harms to human health and longevity worldwide associated with CV events.

Natural products can facilitate a multi-component, multi-target, multi-channel, and multi-dimensional overall treatment networks. Thus, natural products represent alternative resources for developing new drugs, with higher efficiency, better safety, and fewer side effects. Moreover, natural products can play essential roles in preventing and treating many human diseases, including CVDs, metabolic syndromes, cancer, diabetes, obesity, and neurological disorders.

Diosgenin, a well-known steroid sapogenin, occurs widely in various medical plants, and is mainly isolated from Dioscoreaceae, Agavaceae, Amaryllidaceae, Liliaceae, Solanaceae, Scrophulariaceae, Amaryllidaceae, Leguminosae, and Rhamnaceae. The best-known source of various steroidal saponins, including spirostane and furostane types, is fenugreek (Trigonella foenum graecum) seeds. In recent years, diosgenin has attracted increasing attention due to its efficacy in treating various metabolic diseases, including diabetes, CVDs, neurological disease, osteoporosis, and hyperlipidemia, in addition to anti-cancer effects, which are mediated via multiple targets and regulate various signals. Numerous animal experiments and clinical trials have shown that diosgenin can reduce blood lipids by lowering plasma low-density lipoprotein (LDL) and increasing high-density lipoprotein (HDL). Cholesterol lowering drug cholestyramine can combine with bile acid (BA) to form insoluble complex and prevent its reabsorption. Compared with the impact of cholestyramine, diosgenin can interfere with the absorption of exogenous and endogenous cholesterol, promote the secretion of cholesterol into bile, and increase the excretion of neutral sterols without affecting the bile and fecal excretion of bile acid. The effect of diosgenin combined with clofibrate in reducing plasma LDL is more robust than that of a single drug; hence, diosgenin can be combined with other lipid-lowering medications to enhance their effects. Further, diosgenin has demonstrated outstanding potential for lowering lipids in clinical trials and animal experiments and represents a new avenue of exploration for achieving lipid reduction.

In this paper, we elaborate the detailed mechanism underlying lipid metabolism regulation by diosgenin. As shown in Figure 1, this includes the effects of diosgenin in inhibiting intestinal lipid absorption, regulating cholesterol transport, promoting cholesterol conversion into bile acid and its excretion, inhibiting endogenous lipid biosynthesis, antioxidation effects, regulating lipoprotein lipase activity, and regulating transcription factors related to lipid metabolism.

**Physicochemical Properties of Diosgenin**

Diosgenin (3β-Hydroxy-5-spirostene) is a C27 spironosteroidal saponin of the spirosterol steroid family that participates in various physiological and biochemical activities. Diosgenin is structurally similar to cholesterol and other steroids, with molecular formula C\(_{27}\)H\(_{42}\)O\(_3\), density 1.1 ± 0.1 g/cm\(^3\), and relative molecular mass 414.63. Diosgenin is the primary precursor of various pharmacologically active steroids, including corticosteroids and oral contraceptives and takes the form of a white acicular crystal or light amorphous powder, which is thermally and chemically stable under various physical conditions. The melting point of diosgenin is above 200°C and the compound is relatively stable under light, but unstable under hydrochloric acid, which causes its rapid decomposition. Diosgenin has low solubility, due to its strong hydrophobicity; its solubility in water is approximately 0.7 ng/mL. Nevertheless, it is highly soluble in most nonpolar organic solvents (such as chloroform, dichloroethane, propanol, ethyl acetate, and propyl acetate) and some polar solvents (including acetone, methanol, and anhydrous ethanol).

**Sources of Diosgenin**

Diosgenin is a natural steroidal saponin, which is derived from the hydrolysis of dioscin. Diosgenin can be commercially extracted from several plants, including Trigonella, Costus, Aletris, Smilax, and many species of Dioscorea. The primary source of diosgenin is fenugreek seeds. The content of saponins in fenugreek seeds is 169 g/kg. After hydrolysis for 1 h, the saponins are completely removed and sapogenin release is maximal.
Extracts of hydrolyzed fenugreek and quinoa contain the highest fraction of sapogenin and minor fractions of phytosterol and tocopherol. Diosgenin is an important material for the synthesis of steroid hormone medicines. For example, dehydroepiandrosterone can be produced semi-synthetically from natural precursors, primarily diosgenin. Traditionally, diosgenin has been extracted from the rhizome of *Dioscorea zingiberensis* C. H. Wright by acid hydrolysis. More recently, a new method of direct penicillin biotransformation, that is environmentally-friendly, simple, and energy-saving, has been developed and is considered a potential substitute for acid hydrolysis in the diosgenin extraction industry.

**The Pharmacological Mechanism Underlying the Use of Diosgenin for Treatment of Hyperlipidemia**

Diosgenin has numerous pharmacological effects, including anti-tumor activity, improving CV function, regulating immunity, causing anti-platelet aggregation, and lowering blood lipids. In recent years, the lipid-regulating function of diosgenin has attracted increasing attention among researchers. In humans, lipid homeostasis is regulated by homeostatic intestinal absorption mechanisms, endogenous lipid biosynthesis and metabolism, cholesterol transport, cholesterol conversion to bile acid, and biliary excretion. The metabolic enzymes and receptors involved in lipid metabolism are regulated by various transcription factors. The function of diosgenin in treating hypolipidemia through regulating the dynamics of different parts of the metabolic cycle is illustrated in Figure 3. The experimental design, pharmacological evidence, and potential mechanism of diosgenin against hyperlipidemia are summarized in Table 1.
Inhibition of Intestinal Lipid Absorption

Intestinal absorption from the diet is an important source of serum lipids. Cholesterol absorption is a key regulation target of lipid metabolism in humans, because it determines the amount of endogenous bile and cholesterol retained in the diet, thus affecting cholesterol homeostasis. Fenugreek seeds containing diosgenin induced a significant reduction of plasma cholesterol in diabetic dogs, associated with interference in cholesterol absorption. Further, an in vivo experiment showed that intraperitoneal injection of 0.5 mg/kg protodioscin, a steroidal saponin similar to diosgenin from Dioscorea nipponica rhizomes, could significantly reduce blood cholesterol by 40% in male Sprague-Dawley (SD) rats fed a high-fat diet (HFD). Researchers also investigated the inhibitory effect of diosgenin on lipid absorption using experiments on cynomolgus macaques. The macaques were fed a semi-purified diet containing 0.1% cholesterol or a similar diet containing 1% diosgenin during two 3-week periods, and received a standard chow diet for 5 weeks between the two experimental periods. The results showed that diosgenin reduced cholesterol from 292 to 172mg/dl and intestinal absorption of exogenous cholesterol from 62.4% to 26.0%, as well as increasing net endogenous cholesterol secretion from −0.8 to 93.5 mg/day. Niemann-Pick C1-Like 1 (NPC1L1) is a polytopic transmembrane protein with a critical role in cholesterol absorption. Blocking NPC1L1 endocytosis significantly reduces cholesterol endocytosis and hepatic NPC1L1 has a direct role in regulating bile cholesterol excretion and hepatic/blood cholesterol levels. Expression of NPC1L1 in the 0.15 or 0.3 g/kg diosgenin group showed a dose-dependent decrease compared with the HFD group, demonstrating that diosgenin could reduce intestinal absorption by inhibiting NPC1L1. Both diosgenin and total saponins of yellow yam can significantly reduce blood cholesterol content, where the absolute dose of diosgenin comprises only half of the total saponins in yellow yam. The anti-hypercholesterolemia effect of diosgenin was superior to that of total saponins from yellow yam, likely because the polarity and spatial structure of diosgenin are very similar to those of cholesterol, suggesting that diosgenin can likely be dispersed into metacolloids via bile acid activity, and then absorbed directly by...
| Model | Diosgenin Dose | Duration | Effects on the Plasma Lipid Profile and Transcription Factors | Pharmacological Effect | Reference |
|-------|----------------|----------|-------------------------------------------------------------|------------------------|-----------|
| HFD[^] Male SD[^] rats | Protodioscin (0.5 mg/kg/d); intraperitoneal injection | 15–28 days | TC↓, LDL↓, HDL↑, HDL/ LDL↑ | Inhibited HMG-CoA reductase on endoplasmic reticulum | [37] |
| HFD SPF[^] Male SD rats | 0.15, 0.3 g/kg/d; intragastrically | 4 or 8 weeks | FTC↓, TTC↓, TC↓, TG↓, LDL-C↓, NPC1L1↓, ABCG5↑, ABCG8↑, LXR-α↓ | Ameliorated hepatic steatosis and decreased the villi height and tunica mucosa thickness; Reduced cholesterol absorption; Increased cholesterol excretion | [21] |
| HCD[^] Male Wistar rats | 0.5g/100g orally | 4 weeks | TC↓, TG↓, HDL-C↑, LDL-C↓ | Reduced Cholesterol absorption in the intestine and/or increased Cholesterol excretion from the liver; Increased bile acid and Cholesterol excretions | [44] |
| STZ[^] Male Wistar rats | 40 mg/kg b.w. orally | 45 days | TC↓, TG↓, Phospholipids↓, FFA↓, HMGCR↓ | Decreased cholesterol synthesis | [52] |
| HFD+ STZ Male SD rats | 40, 80 mg/kg b.w. orally | 14 days | TC↓, TG↓, SOD↑, GPX↑, GSH↑, TBARS↓, PPARγ↑, PPARα↑ | Promoted pre-adipocytes differentiation; Antioxidation modulating oxidative stress | [68] |
| HFD Male SD rats | 22.1, 44.2, 88.4 mg/kg/d orally | 6 weeks | TC↓, TG↓, LDL-C↓, GSH-Px↑, NOS↑, MDA↓, SOD↑, LPL↑, HL↑ | Antioxidation and modulating oxidative stress; Attenuated H2O2-induced cytotoxicity and increased the cell viability; Accelerated lipids metabolism; Decreased cholesterol absorption and increased biliary cholesterol secretion; | [74] |
| HFD Male C57 mice | In drinking water; 5 mg/L every 2 days | 4 weeks | PPARγ1↓, PPARγ2<sup>↑</sup>, Mest<sup>↑</sup>, MCP-1<sup>↑</sup>, IL-6<sup>↑</sup>, ROS<sup>↑</sup> | Ameliorated metabolic dysfunction; Inhibited adipocyte differentiation | [97] |
| Gestational diabetes-induced C57BL/KsJ[^][^][^] (wild type, homozygous) and C57BL/KsJ<sup>db/db</sup> (db/+ heterozygous) mice | Protocol 1: 10, 20 mg/kg b.w; Protocol 2: 20mg/kg intragastric tube | 4 weeks | TBARS↓, SOD↑, CAT↑, GSH↑, TC↓, TG↓, LDL↓, SREBP-1<sup>↑</sup>, FAS<sup>↑</sup>, SCD-1<sup>↑</sup>, ACC<sup>↑</sup> | Antioxidation and regulation of oxidative stress; Inhibited the mRNA induction of lipogenic genes | [86] |
| HCD Male SD rats | 0.1%, 0.5% diet orally | 6 weeks | ALT↑, AST↑, TC↓, HDL-C↑, HDL/TC↑, GSH-Px↑, SOD↑, TBARS↓ | Liver protective effect; Antioxidation and regulation of oxidative stress; protection against lymphocyte DNA damage in both unstressed and stressed cells; Inhibited pancreatic lipase activity | [71] |

(Continued)
### Table 1 (Continued)

| Model                                    | Diosgenin Dose                  | Duration | Effects on the Plasma Lipid Profile and Transcription Factors                                                                 | Pharmacological Effect                                                                 | Reference |
|------------------------------------------|---------------------------------|----------|---------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-----------|
| HFD Male KK-Ay/Ta Jcl mice (obese diabetic model) | 0.5%, 2.0% fenugreek orally   | 4 weeks  | TG\_↓, SREBP-1\_↑, FAS\_↑, SCD-1\_↑, ACC\_↑, LXR\_α↓                                                                 | Inhibited the mRNA induction of lipogenic genes; Inhibited hepatic steatosis            | [53]      |
| HFD KK-Ay/Ta Jcl mice (obese diabetic model) | 0.5%, 2% fenugreek orally     | 4 weeks  | aP2\_↑, LPL\_↑, Glut4\_↑, PPARγ\_↑, MCP-1\_↑, TNF-α↓, adiponectin\_↑                                                                 | Enhanced insulin sensitivity; Promoted adipocyte differentiation and inhibited obesity-related inflammation | [72]      |
| HCD Male New Zealand White rabbits       | 50 g/kg 50 mesh-size, 50 g/kg nanoscale Dioscorea pseudojaponica orally | 8 weeks  | TC\_↓, TG\_↓, AMPK\_↑, ACC\_↓                                                                                               | Prevented lipid accumulation within liver tissue; Accelerated lipid catabolism          | [54]      |
| Semipurified-diet + 0.1% cholesterol female cynomolgus macaques | 1% die orally                  | 3 weeks  | TC\_↓, TG\_↑                                                                                                                | Increased cholesterol excretion                                                        | [38]      |
| Male apoE KO mice                        | 1% (w/w) orally                | 8 weeks  | TC\_↑, FC\_↑, CE\_↑, ABCA1\_↑, miR-19b↓                                                                                      | Enhanced macrophage cholesterol efflux; Inhibited macrophage cholesterol accumulation; accelerated RCT and improved plasma lipid profile; Inhibited aortic lipid deposition and atherogenesis | [63]      |
| HFD Male SD rats                         | 0.5%, 1% (w/w) orally          | 16 weeks | HDL\_↑, LDL\_↑, TG\_↑, ALT\_↑, pAMPK\_↑, pACC\_↑, AMPK\_↑, ACC\_↑, SREBP1-c\_↑, LXRα↓                                    | Increased AMPK and ACC phosphorylation; accelerated lipid catabolism                  | [91]      |
| 45% kcal-fat content male Wistar rats    | 20, 40, 80 mg/kg for mice and 15, 30, 60 mg/kg for rats orally | 8 weeks  | AST\_↑, ALT\_↑, TG\_↑, TC\_↑, FFA\_↑, SREBP-1\_c\_↑, CPT\_↑, FAS\_↑, SCD\_↑, FoxO\_1\_↑, ATGL\_↑, SOD\_↑, MDA\_↑, GSH\_↑, SIRT1↓ | Improved hepatic lipid metabolism; decreased triacylglycerol accumulation               | [87]      |
| HepG2 cells; THP-1 monocytic cells       | Protodioscin, pseudoprotodioscin, methylprotodioscin (5μm, 10μm, 25μm) | 24h; 48h | ABCA1\_↑, SREBP-1\_↑, SREBP-2\_↑, LXRα\_↑, PCSK9\_↑, FAS\_↑, ACC\_↑, LDLR\_↑                                                                 | Inhibited cholesterol triglycerides synthesis; accelerated RCT and improved plasma lipid profile; | [64]      |
| Human THP-1 monocytic cells; HepG2 cells | Methyl protodioscin (100μm)    | 24h      | SREBP1\_c\_↑, SREBP2\_c\_↑, miR-33a\_b\_↑, ABCA1\_↑, HMGCR\_↑, FAS\_↑, ACC\_↑, LXRα\_↑                             | Inhibited cholesterol triglycerides synthesis                                           | [45]      |
| C57BL/6 male mice; Wistar male rats      | Acute experiment: 28, 56, 84 mg/kg/d; chronic test: 20, 40, 60mg/kg/d; intragastrically | Acute experiment: 2 weeks; chronic test: 12 weeks | AST\_↑, ALT\_↑, TG\_↑, TC\_↑, SOD\_↑, MDA\_↑, GSH\_↑, GSH-Px\_↑, GSR\_↑, TNF-α\_↑, IL-6\_↑, p38\_↑, pERK\_↑, pJNK\_↑, CYP2E1\_↑, PPARα\_↑, CPT\_↑, MCAD\_↑ | Reduced the oxidative stress, Inflammatory cytokine production, apoptosis and liver steatosis | [70]      |
Table 1 (Continued).

| Model          | Diosgenin Dose       | Duration | Effects on the Plasma Lipid Profile and Transcription Factors                                      | Pharmacological Effect                                                                 | Reference |
|----------------|----------------------|----------|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-----------|
| HFD C57BL/6j male mice | 50, 100 dioscin mg/kg/d intragastrically | 7 weeks  | SREBP-1c↑, FAS↑, GLUT4↑, pAMPK↑, pACC↑, p38↑, pERK↓                                                | Inhibited cholesterol triglycerides synthesis; Increased AMPK and ACC phosphorylation; | [57]      |
| SW480 cell      | 6.21 μg/mL           | 24h; 48h | ACC↓, FAS↓, PPARγ↑, LDLR↑                                                                        | Inhibited the mRNA induction of lipogenic genes; decreased cholesterol absorption        | [88]      |
| HFD Male SD rats| 150, 300 mg/kg/d, intragastrically | 8 weeks  | TC↓, TG↓, LDL-C↓, HDL-C↑, SRB1↑, CES-1↑, CYP7A1↑, FXR↓                                         | Accelerated hepatic RCT; enhanced cholesterol elimination                                | [49]      |
|                | 1% (1g/100g)         |          |                                                                                                 |                                                                                         |           |

Abbreviations: *HFD, High-fat diet-fed; **SD, Sprague–Dawley; **SPF, specific-pathogen-free; **HCD, high-cholesterol diet; **STZ, Streptozotocin-Induced; **Mest, mesoderm specific transcripts; **MCP-1, monocyte chemoattractant protein.

the intestine. When diosgenin and cholesterol are both present, diosgenin competes for bile acid binding to inhibit cholesterol absorption. Overall, these results indicate that diosgenin can inhibit lipid absorption by downregulating NPC1L1 expression and competing with cholesterol for bile acids in the intestinal tract.

Regulation of Cholesterol Transport
In addition to blood cholesterol and triglycerides, lipoproteins, such as HDL and LDL, also have important roles in lipid metabolism, as they function to transport lipids and cholesterol that are generally insoluble in blood. Kuang et al. applied diosgenin to the lipogenic normal human liver (L02) cell model, and the results showed that diosgenin could up-regulate expression of Caveolin-1 protein, which is closely related to cholesterol transport, and reduce intracellular cholesterol levels. Protodioscin has potent HDL and LDL (especially LDL) lowering effects. Numerous studies have shown that HDL-C concentration is inversely correlated with CVD risk; hence, raising plasma HDL-C levels may protect against CVD.

In rats fed a high-cholesterol diet (HCD), supplementation with 0.5/100 g diosgenin for 4 weeks led to a slight increase in serum HDL-C and fecal bile acid levels, and a decrease in lipid droplet size. Sterol regulatory element-binding proteins (SREBPs) regulate the balance of LDL, HDL, and triglyceride levels in vivo. In human THP-1 macrophages, methyl protodioscin (MPD) inhibits SREBP1c and SREBP2 transcription and decreases levels of microRNA 33a/b, which is encoded in SREBP gene introns, leading to a corresponding increase in ATP binding cassette A1 (ABCA1) levels. Since ABCA1 is a key protein in HDL biogenesis, low miR-33a/b levels result in high HDL-C. Further, MPD also decreases expression of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (HMGCR), fatty acid synthase (FAS), and acyl-CoA carboxylase (ACC) genes, which are involved in cholesterol and fatty acid synthesis. Therefore, MPD may increase HDL-C levels, and decrease LDL-C and triglyceride levels.

Scavenger receptor class B type I (SRB1) is a receptor physiologically related to HDL, which participates in reverse transport of cholesterol (RCT) and helps to transport excess cholesterol to the liver in the form of cholesterol ester (CE), and then excrete it into bile and feces. Carboxylesterase 1 (CES-1) exhibits cholesteryl ester hydrolase activity, and contributes to hydrolyzation of HDL-CE to free cholesterol (FC), which is available for bile acid synthesis. Cholesterol 7a-hydroxylase (CYP7A1) is the initial and rate-limiting enzyme in the classical BA synthetic pathway, which regulates the total rate of BA generation. Farnesol X receptor (FXR) is a nuclear receptor with fundamental roles in maintaining BA homeostasis and in maintaining the balance between cholesterol and BA. BAs, specifically hydrophobic BAs, act as ligands for FXR and utilize it in their negative feedback loop.
reduce body weight and blood lipid levels of rats fed a HFD, and significantly improve liver steatosis and intestinal structure. Further, diosgenin can increase the expression of SRB1, CES-1, and CYP7A1 in rat liver and inhibit FXR-mediated signal transduction, as well as increasing SRB1 and CES-1 expression in rat intestine, inhibiting cholesterol absorption, and promoting RCT. Hence, diosgenin promotes RCT and cholesterol clearance through the SRB1/CES-1/CYP7A1/FXR pathway, which suggests potential new approaches to alleviate hypercholesterolemia. Together, the results above indicate that diosgenin can increase HDL-C and decrease LDL-C and very low-density lipoprotein (VLDL) cholesterol (VLDL-C) levels by regulating cholesterol transport, and thus participate in regulating blood lipid levels.

**Inhibiting Endogenous Lipid Biosynthesis**

HMGCR is an endoplasmic reticulum bound peroxisome enzyme that catalyzes the reduction of HMG-CoA to COA and mevalonate, which is a rate-limiting reaction in the de novo cholesterol biosynthesis pathway; it is highly expressed in the liver and plays a central role in the regulation of cholesterol metabolism. It is established that HMGCR inhibitors can effectively reduce plasma cholesterol levels in most animals, including humans and these inhibitors are widely used as statins to reduce cholesterol levels by inhibiting cholesterol synthesis. Hao et al showed that oral administration of diosgenin (40 mg/kg orally for 45 days) could significantly reduce mRNA levels encoding HMGCR in the liver of diabetic rats, suggesting that diosgenin can significantly reduce cholesterol synthesis. Diosgenin may inhibit cholesterol biosynthesis by blocking the substrate from entering the active site of the HMGCR enzyme. Uemura et al reported that diosgenin (5 and 10 mmol/l) decreased triglyceride content and mRNA expression levels of genes involved in lipid synthesis (FAS, stearoyl-CoA desaturase 1 (SCD-1), and ACC) by inhibiting SREBP-1c mRNA expression, resulting in inhibited lipid accumulation in hepatocellular carcinoma (HepG2) cells. A study to investigate the lipid-lowering effects of different granule treatments (50 g/kg 50 mesh-size flour or 50 g/kg nanoscale flour) showed that both Dioscorea pseudojaponica particle types could activate adenosine 5’-monophosphate-activated protein kinase (AMPK) and inactivate ACC, as demonstrated by increased levels of phosphorylated enzyme. AMPK activation increases the rate of the catabolic (ATP production) pathway and reduces the rate of the anabolic (ATP utilization) pathway. Cheng hypothesized that diosgenin can stimulate AMPK activation, promote free fatty acid (FFA) decomposition and, under the synergistic effect of liver X receptor alpha (LXRs), inhibit SREBPIC and reduce triglyceride synthesis. Poudel et al demonstrated that diosgenin targets the AMPK/MAPK pathway, suppresses mitotic clonal expansion during the early phase of adipogenesis, and decreases the expression of adipogenic transcription factors in 3T3-L1 cells during adipogenesis. At a dose of 4 µM, diosgenin inhibited lipid accumulation in 3T3-L1 cells, but did not affect cell viability. Further, diosgenin can also regulate weight and fat accumulation induced by HFD in obese mice. In summary, diosgenin inhibits one or several links in the cholesterol and triglyceride biosynthetic pathways, thereby reducing cholesterol and triglyceride levels.

**Promoting Conversion of Cholesterol into Bile Acid and Excretion**

The classical route for the human body to remove cholesterol lipid is via promotion of cholesterol excretion into biliary cholesterol, the conversion of cholesterol into bile acid, and its subsequent fecal excretion. The ATP-binding cassette (ABC) transporters, G5 (ABCG5) and G8 (ABCG8), are hemi-transporters, which play an important role in preventing the accumulation of dietary sterols (including cholesterol and phytosterols) in the body. Li et al reported that, after treatment with 0.15 or 0.3 g/kg diosgenin, ABCG5/G8 expression was increased in the liver and intestine of HFD rats, suggesting that it can promote bile cholesterol secretion. Temel et al showed that fecal excretion of neutral sterols (cholesterol and its bacterial metabolites) in wild-type mice fed with 0.1% diosgenin increased from 4.2 to 52 µmol/day/100 g body weight. Compared with wild-type mice receiving a control diet, the fecal neutral sterol excretion of NPC1L1 knockout mice was also significantly increased, from 63 to 140 µmol/day/100 g body weight. This study demonstrated that diosgenin promotes fecal cholesterol excretion independently of NPC1L1-mediated cholesterol absorption, and that diosgenin may facilitate fecal cholesterol loss to a greater extent in NPC1L1 knockout mice than in wild-type mice. ABCA1 mediates the transfer of cellular phospholipids (PL) and FC to apolipoprotein A-I (ApoA-I) and related proteins in extracellular medium, acting as a lipid transporter. Diosgenin can promote ABCA1 expression...
in macrophages by inhibiting miR-19b levels, and accelerate macrophage cholesterol efflux through the ABCA1 pathway and RCT process. In HepG2 cells, 25 µm pseudoprotodioscin (PPD), a steroidal saponin similar to diosgenin, significantly increased levels of ABCA1 protein and mRNA, and promoted ApoA-1 mediated cholesterol excretion. The underlying mechanism involves PPD inhibition of SREBP1c and SREBP2 transcription by reducing microRNA33a/b levels, leading to increased ABCA1. In summary, diosgenin can promote the conversion of cholesterol to bile acid and increase its excretion in various ways; however, details of the complex molecular mechanisms involved remain to be clarified.

Oxidative Stress and Anti-Oxidant Properties

Oxidation-reduction equilibrium is essential to maintain the normal operation of vital cell functions. Oxidative stress is common in some diseases, including cancer, CVD, atherosclerosis, and diabetes. Endogenous markers of oxidative stress include superoxide dismutase (SOD), glutathione peroxidase (GPx), and reduced glutathione (GSH). During oxidative stress, phospholipids in cell membranes are oxidized by thioarbituric acid reactive substances (TBARS), which hinder their biological functions. Diosgenin has potent in vitro anti-oxidative and in vivo anti-inflammatory activities and participates in glucose metabolism, reduces oxidative stress, increases cell viability, and decreases reactive oxygen species levels. Saneeetha et al. assessed the antioxidant status of experimental rat liver and heart tissue samples treated with and without diosgenin. The rats were fed with an HFD for 8 weeks and then received streptozotocin (STZ) injection to induce a type 2 diabetes model. GSH levels were higher in animals treated with diosgenin (40 mg/kg, 80 mg/kg), although they did not reach the range of those in normal rats. Diosgenin can also maintain SOD and GPX activities and control TBARS production. Rats with chronic renal failure (CRF) were administered diosgenin orally (40 mg/kg/day), and subsequent results demonstrated that diosgenin increased GSH levels and restored endothelial nitric oxide synthase (eNOS) mRNA expression. Further, diosgenin inhibits dyslipidemia and angiotensin converting enzyme (ACE) activity caused by CRF. Overall, data published to date show that diosgenin has potential to protect blood vessels from oxidative stress and dyslipidemia. Xu et al. found that dioscin significantly attenuated the increase in malondialdehyde levels caused by ethanol and significantly elevated SOD, GSH, GSH-Px, and GSR levels. These data indicate that dioscin has an excellent protective effect against ethanol-induced liver injury by reducing oxidative stress, inflammatory cytokine production, apoptosis, and liver steatosis. Further, diosgenin acts as an antioxidant in cell membranes, which may provide protection against oxidative damage of polyunsaturated fatty acids. Fenugreek, which contains diosgenin, can improve glucose metabolism disorder caused by HFD by promoting adipocyte differentiation, inhibiting inflammation of white adipose tissue, and miniaturizing adipocytes. Numerous studies have demonstrated that diosgenin can regulate blood lipids by removing excessive free radicals and reducing physiological lipid deposition.

Regulating Lipase Activity

Hepatic lipoprotein lipase (LPL) and hepatic lipase (HL) are important in the process of lipoprotein hydrolysis. Once lipoproteins are transported to the circulation, specific lipases can help to release their lipid components. The secretory dimer lipases, LPL and HL, hydrolyze triglycerides in lipoproteins and provide FFA for tissues. LPL is secreted from the parenchyma of adipose and muscle to the capillary lumen and acts on VLDL and chylous particles. HL is secreted by hepatocytes and acts on residual lipoprotein and HDL rich in cholesterol. Diosgenin increases LPL and HL activity in a dose-dependent manner. Compared with an HFD rat model group, rats treated with diosgenin (132.8 mg/kg) had significantly increased activities of LPL and HL.

Pancreatic lipase (PL) is a dietary lipid digestive enzyme, inhibition of which reduces triglyceride digestion and lipid absorption. Kwon et al. demonstrated that dioscin and diosgenin have strong inhibitory effects on PL activity. After treatment with dioscin (100 mg/kg) or diosgenin (100 mg/kg), the elevation of plasma triacylglycerol concentration was significantly reduced in mice orally injected with corn oil. Further, in an 8-week experiment, rats fed with a HFD containing 2% or 5% Dioscorea nipponica powder exhibited significantly suppressed weight gain and prevented dietary fat absorption relative to controls fed the HFD alone. The cholesterol-lowering effect of saponins from fenugreek has been widely described in literature regarding the treatment of hyperlipidemia. Navarro Del Hierro et al. found that saponin-rich extracts and their hydrolysates from fenugreek and...
Regulating Transcription Factors Related to Lipid Metabolism

The metabolic enzymes and receptors involved in lipid metabolism are regulated by various transcription factors. Molecules established as involved in lipid metabolism include SREBP3,78,79 LXRs,80,81 and peroxisome proliferator activated receptors (PPAR).82,83

SREBP3 directly activate the expression of more than 30 genes, which contribute to the synthesis and uptake of cholesterol, fatty acids, triglycerides, and phospholipids, as well as nicotinamide adenine dinucleotide phosphate cofactors required for the synthesis of these molecules.84 SREBP-1c preferentially enhances the transcription of genes required for fatty acid synthesis, which is a key regulator of lipid synthesis and accumulation.85 Diosgenin can inhibit the increased expression of the sterol regulatory element-binding protein, SREBP-1, and that of its target genes, including FAS, SCD-1, and ACC.86 Mechanistic studies demonstrated that dioscin can regulate the expression levels of downstream proteins, including SREBP-1c, carnitine palmitoyl transferase, FAS, SCD, forkhead box O1, and adipose triglyceride lipase, by regulating the Silent information regulator of transcription 1 (SIRT1)/AMPK signaling pathway, thus significantly reducing lipid metabolism.87 One study reported significant down-regulation of ACC and FAS, alongside up-regulation of PPARγ and LDL receptor (LDLR), genes at the mRNA level in SW480 cell lines treated with 6.21 µg/mL diosgenin.88 These findings indicate that SREBP3 is a key hub in diosgenin regulation of abnormal lipid metabolism.

LXRs, particularly liver LXRα, have important roles in the transcriptional regulation of lipid metabolism. As a cholesterol sensor, the nuclear receptor, LXR, is a crucial factor in regulating cholesterol homeostasis. LXRα activation can promote the RCT process, cholesterol catabolism, and cholesterol excretion.81 By contrast, LXR agonists increase hepatic and plasma levels of triglyceride in mice, owing to enhanced fatty acid biosynthesis and VLDL secretion.89 Activated LXRs can promote cholesterol metabolism; however, they inevitably produce classical lipogenic side effects. SREBP1 is a significant target of LXRα in upregulating lipogenesis, LXR enhances fatty acid synthesis by activating SREBP1c transcription, which in turn transactivates lipogenic genes. LXR also directly stimulates the transcription of specific lipogenic genes, including acetyl-CoA carboxylase α (ACACA) in chick embryos and fatty acid synthase (FASN) in human cells.90 Diosgenin (10, 25, and 50 µM) significantly inhibited the accumulation of TG and the increase of SREBP-1c mRNA in HepG2 cells induced by high glucose levels. In addition, compared with the model group, diosgenin (0.5% or 1% w/w) treated rats fed with a HFD also exhibited significantly suppressed LXRα levels.91 These data demonstrate that diosgenin may influence fatty acid metabolism by regulating the LXRα/SREBP-1c signaling pathway. To date, there has been insufficient study of whether diosgenin can regulate cholesterol metabolism-related pathways through LXRs to maintain cholesterol homeostasis. It will be of great significance to further ascertain the specific mechanism underlying diosgenin-mediated regulation of LXRs.

PPARs are members of the nuclear receptor superfamily, and their physiological functions are related to metabolism, energy homeostasis, and cell development and differentiation. Three PPARs have been identified: PPARα, PPARγ, and PPARβ/δ.92 Many PPAR agonists have been synthesized to treat metabolic diseases, particularly dyslipidemia and type 2 diabetes mellitus (T2DM), due to their crucial metabolic regulatory roles and excellent druggability.93 Hepatic PPARα stimulates fatty acid catabolism by modulating the expression of LPL, apolipoprotein genes, fatty acid transport and oxidation genes, and genes involved in HDL metabolism and ketone synthesis. Therefore, PPARα activators have vital roles dyslipidemia treatment.94 Sangeetha et al. detected a slight increase in PPARα expression in 3T3-L1 cells treated with diosgenin at 0.5, 1, and 10 µM, but the increase was not as significant as that of PPARγ. PPARγ is mainly expressed in adipose tissue, hematopoietic cells, and the large intestine, and has key roles in lipid and glucose metabolism.95 PPARγ agonists are widely used for T2DM treatment and their clinical efficacy as oral antidiabetic agents is well

quinoa can inhibit PL activity. Although the exact role of sapogenins contained in the hydrolyzed extracts in lipase inhibition remains unclear, the study provided a potential baseline for the development of multi-bioactive products that act against pancreatic lipase and cholesterol absorption simultaneously. In summary, diosgenin reduced dietary fat decomposition and absorption in the digestive organs by reducing the hydrolytic activity of these key enzymes, thus alleviating the symptoms of metabolic diseases, such as hyperlipidemia. In future, the regulation of lipase activity by diosgenin warrants further research.
established; however, there is controversy about the effect of diosgenin on PPARγ, one study showed that diosgenin can down-regulate PPARγ expression and activity, and inhibit adipocyte differentiation. Another study showed that diosgenin is a selective agonist of PPARγ and up-regulates its expression. This may be why adipogenesis was observed in 3T3-L1 cells, resulting in reduced circulating free lipids in diabetic animals, and diosgenin may be considered as a hypolipidemic drug. At present, the mechanism underlying of the effects of diosgenin on PPARs are unclear. In silico docking studies showed that PPARα and PPARγ both interact with diosgenin, while the efficiency of diosgenin binding to PPARγ is higher than that of PPARα. This raises a question of whether diosgenin may be a dual agonist of both PPARα and PPARγ. A recent study showed that integrative application of PPARα and PPARγ agonists may decrease hepatic lipid accumulation, oxidative stress, and production of inflammatory cytokines, which may be due to the synergistic effect of PPARα and PPARγ in regulating the expression of the downstream target genes, SREBP-1c, FAS, DGAT, LPL, and NF-jB. As synthetic ligands have many side effects, using natural agonists, such as diosgenin, may be a safe alternative method for targeted regulation of lipid metabolism. Diosgenin can also be considered a dual agonist, which could provide a better balance between efficacy and side effects, compared with single agonists or dual agonists with varying potency.

In summary, diosgenin participates in regulating lipid metabolism through multiple targets and pathways. The underlying mechanisms are highly complex and more animal studies and clinical trials are needed to unravel the details in the future.

Advantages and Limitations of Diosgenin

Plant extracts and their derivatives are widely used to treat various diseases because of their high bioavailability, low side effects, and low cost. In recent years, diosgenin and its derivatives have been the focus of considerable research efforts worldwide. Numerous studies have elucidated the pharmacological effects of diosgenin and its derivatives on various diseases, such as cancer, diabetes, and osteoporosis. Diosgenin can be obtained from various medicinal plants, particularly fenugreek seeds, which represent a comprehensive and low-cost source. In general, diosgenin and other plant-derived compounds have lower toxicity than chemical drugs. Notably, diosgenin has good cytotoxic activity toward HepG2 cells, but relatively low toxicity to L02 cells, indicating a degree of selectivity between normal and tumor cells. We infer that steroidal saponins, including diosgenin, do not show any significant toxicity at conventional dosages. Due to the poor water solubility and strong hydrophobicity of diosgenin, its oral bioavailability is not ideal, and numerous diosgenin formulation strategies have been applied to overcome these issues, including liquid crystalline (LCs) and b-cyclodextrin (b-CD) complexes, nanocrystals, and soluplus-mediated diosgenin Amorphous Solid Dispersion (ASD) technology.

In recent decades, ASDs have been the subject of increased research interest, as they can increase the oral bioavailability of poorly soluble drugs. The aqueous solubility of optimized ASDs was significantly improved due to the amorphization of diosgenin and the molecular interactions between diosgenin and soluplus. Furthermore, pharmacokinetic studies in rats revealed that the bioavailability of diosgenin from ASDs was improved approximately five-fold. Hence, diosgenin ASDs, with their high solubility, high bioavailability, and high stability, represent a promising route toward pharmaceutical applications. Simultaneously, although numerous preclinical studies have demonstrated that diosgenin has reliable lipid metabolism regulation function, clinical research data remain limited. Therefore, it will be necessary to verify the therapeutic effects of diosgenin on human hyperlipidemia via additional clinical trials in the future.

Conclusion and Future Prospects

Phytochemicals found in medicinal or edible plants have remarkable biological activity, high safety, low or no toxicity, and represent alternative resources for developing new drugs. Diosgenin is a natural steroidal saponin, with potential for broad application. Numerous studies have confirmed the great potential for use of diosgenin in the treatment and prevention of hyperlipidemia. In this paper, we reviewed the pharmacological mechanism underlying the effects of diosgenin in the treatment of hyperlipidemia, including its roles in inhibition of intestinal lipid absorption, regulation of cholesterol transport, promotion of cholesterol conversion into bile acid and excretion, inhibition of endogenous lipid biosynthesis, effects on antioxidation and lipoprotein lipase activity, and regulation of transcription factors related to lipid metabolism. Combined with research progress regarding
the pathological mechanism underlying dyslipidemia, related pathways were discussed. Drugs to treat dyslipidemia mainly reduce blood lipids by regulating the kinetics of different parts of the metabolic cycle. Researchers worldwide are using network pharmacology, chromatography, mass spectrometry, and GCMS to study the pathogenesis and treatment of hyperlipidemia and the resulting findings will provide a scientific basis for understanding the “multi component-multi target-multi pathway” mechanisms underlying the effects of diosgenin on hyperlipidemia.

In addition, several new diosgenin delivery systems have been developed by combining diosgenin with b-CD, LC, nanocrystalline, and ADS technologies, to improve the water solubility and bioavailability of the compound, which has been beneficial to the clinical application and biological activity of diosgenin. Drugs containing diosgenin are already marketed in China; however, there have been few reports on clinical trials of diosgenin for treating dyslipidemia, making it is difficult to assess the potential clinical benefits of diosgenin for treating human hyperlipidemia. Thus, more clinical trials are needed to ensure the effectiveness and safety of diosgenin when used to regulate human lipid metabolism. Diosgenin could be used as a small molecule probe to search for natural-binding partners in vivo that play important roles in reducing blood lipids. In the future, with further study on the mechanisms underlying diosgenin activity, diosgenin can be expected to play a safer and more effective pharmacological role and be appropriately applied in the treatment of disease in the clinic.

**Abbreviations**

CHD, coronary heart disease; VLDL-C, very low-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; CVD, cardiovascular disease; CV, cardiovascular; VLDL, very low density lipoprotein; LDL, low-density lipoprotein; LDLR, low-density lipoprotein receptor; IDL, intermediate-density lipoprotein; HDL, high-density lipoprotein; SD, Sprague-Dawley; HFD, high-fat diet; HCD, high-cholesterol diet; NPC1L1, Niemann-Pick C1-Like 1; SREBP, Sterol regulatory element-binding proteins; SREBP-1, sterol regulatory element-binding protein; SREBP-2, sterol regulatory element-binding protein-2; MPD, methyl protodioscin; ABCA1, ATP binding cassette A1; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; FAS, fatty acid synthase; ACC, acyl-CoA carboxylase; SRB1, scavenger receptor class B type I; RCT, reverse transport of cholesterol; CE, cholesterol ester; CES-1, carboxylesterase 1; FC, free cholesterol; CYP7A1, cholesterol 7α-hydroxylase; BA, bile acid; FXR, farnesol X receptor; FAS, fatty acid synthase; SCD-1, stearoyl-CoA desaturase 1; ACC, acetyl-CoA carboxylase; HepG2, hepatocellular carcinoma; AMPK, adenosine 5’-monophosphate-activated protein kinase; FFA, free fatty acids; LXR, liver X receptor; LXRx, liver X receptor alpha; ABCG5, ATP-binding cassette transporters G5; ABCG5, ATP-binding cassette transporters G8; PL, phospholipids; ApoA-I, apolipoprotein A-I; PPD, pseudoprotodioscin; SOD, superoxide dismutase; GPx, glutathione peroxidase; GSH, glutathione; TBARS, thiobarbituric acid reactive substances; ROS, reactive oxygen species; STZ, streptozotocin-Induced; CRF, chronic renal failure; eNOS, endothelial nitric oxide synthase; ACE, angiotensin converting enzyme; MDA, malondialdehyde; LPL, lipoprotein lipase; HL, hepatic lipase; PL, pancreatic lipase; PPAR, peroxisome proliferator activated receptors; NADPH, nicotinamide adenine dinucleotide phosphate; SIRT1, silent information regulator of transcription 1; ACACA, acetyl-CoA carboxylase α; FASN, fatty acid synthase; T2DM, type 2 diabetes mellitus; L02, normal human liver cells; LCs, liquid crystalline; b-CD, b-cyclodextrin; ASD, amorphous solid dispersion; SPF, specific-pathogen-free; Mest, mesoderm specific transcript; MCP-1, monocyte chemoattractant protein; CM, chylomicron; PCSK9, proprotein convertase subtilisin/kexin type 9.

**Acknowledgments**

We want to thank Liping Zhang for her timely help in revising the grammar and logic of the manuscript. This paper was supported by the National Natural Science Foundation of China (No. 81573945), the Science and Technology Development Project of Shandong Province (No. 2013GSF11902), the National Prestigious Chinese Medicine Doctor Studio of Xinlu Wang Project ([2016]47), and the Science and Technology Development Project of Traditional Chinese Medicine in Shandong Province (Nos. 2013-081 and 2019-0093).

**Disclosure**

The authors report no conflicts of interest in this work.
References

1. Karr S. Epidemiology and management of hyperlipidemia. Am J Manag Care. 2017;23(9 Suppl):S139–S148.
2. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: a report from the American heart association. Circulation. 2018;137(12):e67–e492.
3. Townsend N, Nichols M, Scarborough P, Rayner M. Cardiovascular disease in Europe-epidemiological update 2015. Eur Heart J. 2015;36(40):2696–2705. doi:10.1093/eurheartj/ehv428.
4. Wang XG, Zhao X, Li Y, et al. Research progress of pathogenesis and treatment of hyperlipidemia. J Liaoning Univ Trad Chin Med. 2020;22(12):196–200.
5. Kopin L, Lowenstein C. Dyslipidemia. Ann Intern Med. 2017;167(11):ITC81–ITC96. doi:10.7326/AITC201712050.
6. Holven KB, Ulven SM, Bogsrud MP. Hyperlipidemia and cardiovascular disease with focus on familial hypercholesterolemia. Curr Opin Lipidol. 2017;28(5):445–447. doi:10.1097/MOL.0000000000000449.
7. Strilchuk L, Fogacci F, Cicero AF. Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data. Expert Opin Drug Saf. 2019;18(7):611–621. doi:10.1080/14740338.2019.1620730.
8. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society consensus panel statement on assessment, aetiology and treatment. Eur Heart J. 2015;36(17):1012–1022. doi:10.1093/eurheartj/ehv043.
9. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
10. Thomford NE, Senthene DA, Rowe A, et al. Natural products on small dense LDL levels, LDL particle number and LDL particle size: a clinical review. Lipids Health Dis. 2020;19(1):66. doi:10.1186/s12906-019-01250-6.
11. Talebi S, Bagherinya M, Atkin SL, Askari G, Orafai HM, Sahebkar A. The beneficial effects of nutraceuticals and natural products on small dense LDL levels, LDL particle number and LDL particle size: a clinical review. Lipids Health Dis. 2020;19(1):66. doi:10.1186/s12906-019-01250-6.
12. Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, et al. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33(8):1582–1614.
13. Rodrigues T, Reker D, Schneider P, Schneider G. Counting on small dense LDL levels, LDL particle number and LDL particle size: a clinical review. Lipids Health Dis. 2020;19(1):66. doi:10.1186/s12906-019-01250-6.
14. Chen Y, Tang YM, Yu SL, et al. Advances in the pharmacological activities and mechanisms of diosgenin. Chin J Nat Med. 2015;13(8):578–587.
15. Yuan B, Byrnes DR, Dinssa FF, Simon JE, Wu Q. Identification of polyphenols, glycoalkaloids, and saponins in Solanum scabrum berries using HPLC-UVD-Vis-MS. J Food Sci. 2019;84(2):235–243. doi:10.1111/1750-3841.14424.
16. Krol-Kogus B, Lamine KM, Migas P, Boudjeniba M, Krauze-Baranowska M. HPTLC determination of diosgenin in fenugreek seeds. Acta Pharm. 2018;68(1):97–107. doi:10.2478/aphc-2018-0002.
17. Gong J, Fang K, Dong H, Wang D, Hu M, Lu F. Effect of fenugreek on hyperglycaemia and hyperlipidaemia in diabetes and prediabetes: a meta-analysis. J Ethnopharmacol. 2016;194:260–268. doi:10.1016/j.jep.2016.08.003.
18. Wu FC, Jiang JG. Effects of diosgenin and its derivatives on atherosclerosis. Food Funct. 2019;10(11):7022–7036. doi:10.1039/C9FO00749K.
19. Cai B, Zhang Y, Wang Z, et al. Therapeutic potential of diosgenin and its major derivatives against neurological diseases: recent advances. Oxid Med Cell Longev. 2020;2020:3153082. doi:10.1155/2020/3153082.
20. Wu S, Zhao F, Zhao J, et al. Dioscin improves postmenopausal osteoporosis through inducing bone formation and inhibiting apoptosis in ovariectomized rats. Biosci Trends. 2019;13(3):394–401. doi:10.5582/bst.2019.01186.
21. Li R, Liu Y, Shi J, et al. Diosgenin regulates cholesterol metabolism in hypercholesterolemic rats by inhibiting NPC1L1 and enhancing ABCG5 and ABCG8. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864(8):1124–1133. doi:10.1016/j.bbadis.2019.04.010.
22. Tao X, Yin L, Xu L, Peng J. Dioscin: a diverse acting natural compound with therapeutic potential in metabolic diseases, cancer, inflammation and infections. Pharmacol Res. 2018;137:259–269. doi:10.1016/j.phrs.2018.09.022.
23. Sethi G, Shannumag MK, Warner S, et al. Pro-apoptotic and anti-cancer properties of diosgenin: a comprehensive and critical review. Nutrients. 2018;10(5):5. doi:10.3390/nu10050065.
24. Cayen MN, Dvornik D. Effect of diosgenin on lipid metabolism in rats. J Lipid Res. 1979;20(2):162–174. doi:10.1194/jlr.20S022-S27525(204)0628-5.
25. Liu MX, Zhang FX, Sun LY, Guan DH. Study on regulating blood lipid effects and the mechanism of diosgenin. Arch Tradit Chin Med. 2016;34(04):798–800.
26. Parama D, Borauh M, Kumari Y, et al. Diosgenin, a steroidal saponin, and its analogs: effective therapies against different chronic diseases. Life Sci. 2020;260:118182.
27. Liao AM, Jung H, Yu JW, et al. Synthesis and biological evaluation of arginyl-diosgenin conjugate as a potential bone tissue engineering agent. Chem Biol Drug Des. 2018;91(1):17–28. doi:10.1111/cbdd.13050.
28. Chen FX, Zhao MR, Ren BZ, et al. Solubility of diosgenin in different solvents. J Chem Thermodyn. 2012;47:341–346. doi:10.1016/j.jct.2011.11.009.
29. Chaudhary SA, Chaudhary PS, Syed BA, et al. Validation of a method for diosgenin extraction from fenugreek (Trigonella foenum-graecum L.). Acta Sci Pol Technol Aliment. 2018;17(4):377–385.
30. Selim S, Al Jaouni S. Anticancer and apoptotic effects on cell proliferation of diosgenin isolated from Costus speciosus (Koen.) Sm. BMC Complement Altern Med. 2015;15(1):301. doi:10.1186/s12906-015-0836-8.
31. Kim JK, Park SU. An update on the biological and pharmacological activities of diosgenin. EXCLI J. 2018;17:24–28.
32. Li X, Wang Y, Sun J, et al. Chemotaxonomic studies of 12 Dioscorea species from China by UHPLC-QTOF-MS/MS analysis. Phytochem Anal. 2020;31(2):164–182. doi:10.1002/ pca.2876.
33. Herrera T, Navarro Del Hierro J, Fornari T, Reglero G, Martin D. Acid hydrolysis of saponin-rich extracts of quinoa, lentil, fenugreek and soybean to yield sapogenin-rich extracts and other bioactive compounds. J Sci Food Agric. 2019;99(6):3157–3167. doi:10.1002/jsfa.9531.
34. Sahu P, Gidwani B, Dhongade BH. Pharmacological activities of dehydroepiandrosterone: a review. Steroids. 2020;153:108507. doi:10.1016/j.steroids.2019.108507.
35. Dong J, Lei C, Lu D, Wang Y. Direct biotransformation of dioscin into diosgenin in rhizome of Dioscorea zingiberensis by penicillium dioscin. Indian J Microbiol. 2015;55(2):200–206. doi:10.1007/s12088-014-0507-3.
36. Sauvayre P, Ribes G, Baccou JC, Loubatières-Mariani MM. Implication of steroid saponins and sapogenins in the hypocholesterolemic effect of fenugreek. Lipids. 1991;26(3):191–197. doi:10.1007/BF02054390.
37. Wang T, Choi RC, Li J, et al. Antihyperlipidemic effect of protodioscin, an active ingredient isolated from the rhizomes of Dioscorea nipponica. *Planta Med.* 2010;76(15):1642–1646. doi:10.1055/s-0030-1249960

38. Malinow MR, Elliott WH, McLaughlin P, Upson B. Effects of synthetic glycosides on steroid balance in Macaca fascicularis. *J Lipid Res.* 1987;28(1):1–9. doi:10.1016/S0022-2272(78)38729-0

39. Yamanashi Y, Takada T, Yamamoto H, Suzuki H. NPC1L1 facilitates sphingomyelin absorption and regulates diet-induced production of VLDL-LDL-associated SLP. *Nutrients.* 2020;12(9):2641. doi:10.3390/nu12092641

40. Tang W, Lin J, Ma Y, et al. Ezetimibe restores biliary cholesterol excretion in mice expressing Niemann-Pick C1-like 1 only in liver. *Biochim Biophys Acta.* 2011;1811(9):549–555. doi:10.1016/j.bbala.2011.05.013

41. Ma HY, Zhao ZT, Wang LJ, Wang Y, Zhou QL, Wang BX. Comparative study on anti-hypercholesterolemia activity of diosgenin and total saponin of Dioscorea panthaica. *J Trad Chin Med.* 2002;27(7):51–54.

42. Kuang SY, Li Y, Kuang WD. Effects of diosgenin on cholesterol metabolism and caveolin-1 expression in human hepatocyte L-02. *Chin Pharm.* 2013;24(35):3286–3288.

43. Rhee EJ, Byrne CD, Sung KC. The HDL cholesterol/apoproteinprotein A-I ratio: an indicator of cardiovascular disease. *Curr Opin Endocrinol Diabetes Obes.* 2017;24(2):148–153. doi:10.1097/MED.0000000000000315

44. Kusano Y, Tsujihara N, Masui H, Kozai H, Takeuchi W. Consumption of Japanese yam improves lipid metabolism in high-cholesterol diet-fed rats. *Nutr Sci Vitaminol (Tokyo).* 2016;62(5):330–360. doi:10.3177/jnsv.62.330

45. Ma W, Ding H, Gong X, et al. Methyl protodioscin increases ABCA1 expression and cholesterol efflux while inhibiting gene expressions for synthesis of cholesterol and triglycerides by suppressing SREBP transcription and microRNA 33a/b levels. *Atherosclerosis.* 2015;259(2):566–570. doi:10.1016/j.atherosclerosis.2015.02.034

46. Shen WJ, Azfar S, Kraemer FB. SR-B1: a unique multifunctional receptor for cholesterol influx and efflux. *Annu Rev Physiol.* 2018;80:95–116. doi:10.1146/annurev-physiol-021317-121550

47. Xu J, Xu Y, Xu Y, Yin L, Zhang Y. Global inactivation of carboxylesterase 1 (Ces1/Ces1g) protects against atherosclerosis. *J Lipid Res.* 2018;59(7):1103–1113. doi:10.1194/jlr.R084244

48. Temel RE, Brown JM, Ma Y, et al. Diosgenin stimulation of fecal bile acid synthesis and its activation protects against hypercholesterolemia. *Biochim Biophys Acta Mol Cell Biol Lipids.* 2018;1863(9):1029–1040. doi:10.1016/j.bbalip.2018.06.003

49. Liu S, Jing F, Yu C, Gao L, Qin Y, Zhao J. AICAR-induced activation of AMPK inhibits TSH/SREBP-2/HMGCR pathway in liver. *PLoS One.* 2015;10(5):e0124951. doi:10.1371/journal.pone.0124951

50. Patel SB, Graf GA, Temel RE. ABCG5 and ABCG8: more than a defense against xenosterols. *J Lipid Res.* 2018;59(7):1103–1113. doi:10.1194/jlr.R084244

51. Temel RE, Brown JM, Ma Y, et al. Diosgenin stimulation of fecal bile acid synthesis and its activation protects against hypercholesterolemia. *Biochim Biophys Acta Mol Cell Biol Lipids.* 2018;1863(9):1029–1040. doi:10.1016/j.bbalip.2018.06.003

52. Phillips MC. Is ABCA1 a lipid transfer protein? *J Lipid Res.* 2018. [https://pubmed.ncbi.nlm.nih.gov/29305383/](https://pubmed.ncbi.nlm.nih.gov/29305383/)

53. Lv YC, Yang J, Yao F, et al. Diosgenin inhibits atherosclerosis via suppressing the MiR-19b-induced downregulation of ATP-binding cassette transporter A1. *Atherosclerosis.* 2015;240(1):80–89. doi:10.1016/j.atherosclerosis.2015.02.044

54. Gai Y, Li Y, Xu Z, Chen J. Pseudoprotodioscin inhibits SREBPs and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides. *Fitoterapia.* 2019;139:104393. doi:10.1016/j.fitote.2019.104393

55. Marrocco I, Altieri F, Peluso I. Measurement and clinical significance of biomarkers of oxidative stress in humans. *Oxid Med Cell Longev.* 2017;2017:6501046. doi:10.1155/2017/6501046

56. Gupta DD, Mishra S, Verma SS, et al. Evaluation of antioxidant, anti-inflammatory and anticancer activities of diosgenin enriched Paris polyphylla rhizome extract of Indian Himalayan landraces. *J Ethnopharmacol.* 2021;270:113842. doi:10.1016/j.jep.2021.113842

57. Pi WX, Feng XP, Ye LH, Cai BC. Combination of morroniside and diosgenin prevents high glucose-induced cardiomyocytes apoptosis. *Molecules.* 2017;22(1):163. doi:10.3390/molecules22010163

58. Sangeetha MK, ShriShri Mal N, Atmaja K, Sali VK, Vasanthi HR. PPAR’s and diosgenin a chemico biological insight references. [https://doi.org/10.2147/DMSO.S326054](https://doi.org/10.2147/DMSO.S326054)
70. Xu T, Zheng L, Xu L, et al. Protective effects of dioscin against alcohol-induced liver injury. Arch Toxicol. 2014;88(3):739–753. doi:10.1007/s00204-013-1148-8

71. Son IS, Kim JH, Sohn HY, Son KH, Kim JS, Kwon CS. Antioxidative and hypolipidemic effects of diosgenin, a steroidal saponin of yam (Dioscorea spp.), on high-cholesterol fed rats. Biosci Biotechnol Biochem. 2007;71(12):3063–3071. doi:10.1271/bbb.70477

72. Uemura T, Hira S, Mizoguchi N, et al. Diosgenin present in fenugreek improves glucose metabolism by promoting adipocyte differentiation and inhibiting inflammation in adipose tissues. Mol Nutr Food Res. 2010;54(11):1596–1608. doi:10.1002/mnfr.200900609

73. Koerner CM, Roberts BS, Neher SB. Endoplasmic reticulum quality control in lipoprotein metabolism. Mol Cell Endocrinol. 2019;498:110547. doi:10.1016/j.mec.2019.110547

74. Gong G, Qin Y, Huang W, et al. Protective effects of diosgenin in the hyperlipidemic rat model and in human vascular endothelial cells against hydrogen peroxide-induced apoptosis. Chem Biol Interact. 2010;184(3):366–375. doi:10.1016/j.cbil.2010.02.005

75. Matsuo Y, Matsumoto K, Inaba N, Mimaki Y. Daisaikoto inhibits pancreatic lipase activity and decreases serum triglyceride levels in mice. Biol Pharm Bull. 2018;41(9):1485–1488. doi:10.1248/bpb.b18-00324

76. Kwon CS, Sohn HY, Kim SH, et al. Anti-obesity effect of Dioscorea nipponica Makino with lipase-inhibitory activity in rodents. Biosci Biotechnol Biochem. 2003;67(7):1451–1456. doi:10.1271/bbb.67.1451

77. Navarro Del Hierro J, Casado-Hidalgo G, Reglero G, Martin D. The hydrolysis of saponin-rich extracts from fenugreek and quinoa improves their pancreatic lipase inhibitory activity and hypocholesterolemic effect. Food Chem. 2021;338:128113. doi:10.1016/j.foodchem.2020.128113

78. Zhang F, Sun W, Chen J, et al. SREBP-2, a new target of metformin? Drug Des Devel Ther. 2018;12:4163–4170. doi:10.2147/DDDT.S190094

79. Shimano H, Sato R. SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology. Nat Rev Endocrinol. 2017;13(12):710–730.

80. Schulman IG. Liver X receptors link lipid metabolism and inflammation. FEBS Lett. 2017;591(19):2978. doi:10.1002/1873-3468.12702

81. Wang B, Tontonoz P. Liver X receptors link lipid metabolism and inflammation. FEBS Lett. 2017;591(19):2978. doi:10.1002/1873-3468.12702

82. Wang B, Tontonoz P. Liver X receptors in lipid metabolism, insulin signaling, and beyond. Trends Biochem Sci. 2018;43(5):358–368. doi:10.1016/j.tibs.2018.01.005.

83. Li X, Li Y, Yang W, et al. SREBP-1c overexpression induces triglyceride accumulation through increasing lipid synthesis and decreasing lipid oxidation and VLDL assembly in bovine hepatocytes. J Steroid Biochem Mol Biol. 2014;143:174–182. doi:10.1016/j.jsbmb.2014.02.009

84. Debose-Boyd RA, Ye J. SREBPAs in lipid metabolism, insulin signaling, and beyond. Trends Biochem Sci. 2018;43(5):358–368. doi:10.1016/j.tibs.2018.01.005.

85. Hua S, Li Y, Su L, Liu X. Diosgenin ameliorates gestational diabetes through inhibition of sterol regulatory element-binding protein-1. Biomed Pharmacother. 2016;84:1460–1465. doi:10.1016/j.biopharm.2016.10.049

86. Luo J, Zhang XY, Li J, et al. Diosgenin alleviates non-alcoholic fatty liver disease through adjusting lipid metabolism via SIRT1/AMPK signaling pathway. Pharmacol Res. 2018;131:51–60. doi:10.1016/j.phrs.2018.03.017

87. Mohammad-Sadeghipour M, Mahmodi M, Noroozi Karimabad M, Mirzaei MR, Hajizadeh MR. Diosgenin and 4-hydroxyisocoumarin from fenugreek are regulators of genes involved in lipid metabolism in the human colorectal cancer cell line SW-480. Cell J. 2021;23(4):514–522.

88. Schultz JR, Tu H, Luk A, et al. Role of LXRα in control of lipogenesis. Genes Dev. 2000;14(22):2831–2838. doi:10.1101/gad.850400

89. Xu HY, Luo J, Zhang XY, Li J, Bionaz M. Activation of liver X receptor promotes fatty acid synthesis in goat mammary epithelial cells via modulation of SREBP1 expression. J Dairy Sci. 2019;102(4):3544–3555. doi:10.3168/jds.2018-15538

90. Cheng S, Liang S, Liu Q, et al. Diosgenin prevents high-fat diet-induced rat non-alcoholic fatty liver disease through the AMPK and LXR signaling pathways. Int J Mol Med. 2018;41(2):1089–1095.

91. Cheng HS, Tan WR, Low ZS, Marvalim C, Lee JYH, Tan NS. Exploration and development of PPAR modulators in health and disease: an update of clinical evidence. Int J Mol Sci. 2019;20(20):5055. doi:10.3390/ijms20205055

92. Mirza AZ, Althagafi II, Shamshad H. Role of PPAR receptor in different diseases and their ligands: physiological importance and clinical implications. Eur J Med Chem. 2019;166:502–513. doi:10.1016/j.ejmech.2019.01.067

93. Bougarme N, Weyers B, Desmet SI, et al. Molecular actions of PPARα in lipid metabolism and inflammation. Endocr Rev. 2018;39(5):760–802.

94. Janani C, Ranjitha Kumar BD. PPAR gamma gene-a review. Diabetes Metab Syndr. 2015;9(1):46–50. doi:10.1016/j.dsx.2014.09.015

95. Alam F, Islam MA, Mohamed M, et al. Efficacy and safety of pioglitazone monotherapy in type 2 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials. Sci Rep. 2019;9(1):5389. doi:10.1038/s41598-019-41854-2

96. Wang X, Liu J, Long Z, et al. Effect of diosgenin on metabolic dysfunction: role of ERbeta in the regulation of PPARgamma. Toxicol Appl Pharmacol. 2015;289(2):286–296. doi:10.1016/j.taap.2015.09.015

97. Zhang C, Cui Y, Wang XL, Shang X, Xie ML. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats. Cytokine. 2015;75(1):127–135. doi:10.1016/j.cyto.2015.05.031

98. Nanjan MJ, Mohammed M, Prashanthakumar BR, Chandrasekar MJN. Thiazolidinediones as antidiabetic agents: a critical review. Bioorg Chem. 2018;77:548–567. doi:10.1016/j.bioorg.2018.02.009

99. Gan Q, Wang J, Hu J, et al. The role of diosgenin in diabetes and diabetic complications. J Steroid Biochem Mol Biol. 2020;198:105575. doi:10.1016/j.jsbmb.2019.105575

100. Zhao S, Niu F, Xu CY, et al. Diosgenin prevents bone loss on retinoic acid-induced osteoporosis in rats. J Steroid Biochem Mol Biol. 2016;158:581–587. doi:10.1016/j.jsbmb.2016.08.003

101. Yin H, Zhang MJ, An RF, Zhou J, Huang XF. Diosgenin derivatives as potential antitumor agents: synthesis, cytotoxicity, and mechanism of action. J Nat Prod. 2020;84(3):616–29.

102. Manda VK, Avula B, Ali Z, et al. Characterization of in vitro ADME properties of diosgenin and dioxcin from Dioscorea villosa. Planta Med. 2013;79(15):1421–1428. doi:10.1055/s-0033-1336521
104. Liu P, Zhou JY, Chang JH, et al. Soluplus-mediated diosgenin amorphous solid dispersion with high solubility and high stability: development, characterization and oral bioavailability. *Drug Des Devel Ther.* 2020;14:2959–2975. doi:10.2147/DDDT.S253405

105. Schittny A, Huwyler J, Puchkov M. Mechanisms of increased bioavailability through amorphous solid dispersions: a review. *Drug Deliv.* 2020;27(1):110–127. doi:10.1080/10717544.2019.1704940

106. Banerjee S, Bhattacharjee P, Kar A, Mukherjee PK. LC-MS/MS analysis and network pharmacology of Trigonella foenum-graecum - a plant from Ayurveda against hyperlipidemia and hyperglycemia with combination synergy. *Phytomedicine.* 2019;60:152944. doi:10.1016/j.phymed.2019.152944

107. Ren Y, Wang Z, Wu C, et al. Ultrahigh-performance liquid chromatography with tandem mass spectrometry for the determination of 10 alkaloids in beagle plasma after the oral administration of the three Coptidis rhizoma extracts. *J Ethnopharmacol.* 2019;239:111896. doi:10.1016/j.jep.2019.111896

108. Sozen E, Yazgan B, Sahin A, Ince U, Ozer NK. High cholesterol diet-induced changes in oxysterol and scavenger receptor levels in heart tissue. *Oxid Med Cell Longev.* 2018;2018:8520746. doi:10.1155/2018/8520746